Table 1.

Association between mtDNA content and clinicopathologic variables of node-positive patients receiving either FAC/FEC or CMF adjuvant chemotherapy treatment (adjuvant cohort)

mtDNA lowmtDNA high
Characteristicn (%)n (%)P
Age (at diagnosis)
 ≤4027 (31.0%)19 (21.8%)0.3
 >40–5043 (49.4%)53 (60.9%)
 >5017 (19.5%)15 (17.2%)
Menopausal status (at diagnosis)
 Pre80 (92.0%)74 (85.1%)0.2
 Post7 (8.0%)13 (14.9%)
Tumor size
 T1 (≤2 cm)24 (29.3%)13 (15.3%)0.1
 T2 (>2–5 cm)43 (52.4%)54 (63.5%)
 T3/4 (>5 cm)15 (18.3%)18 (21.2%)
 Unknown52
Nodal status
 1–353 (60.9%)47 (54%)0.4
 >334 (39.1%)40 (46%)
Grade (GGI)
 115 (19.7%)11 (15.7%)0.5
 227 (35.5%)32 (45.7%)
 334 (44.7%)27 (38.6%)
 Unknown1117
ER status
 Negative24 (27.6%)24 (27.6%)1
 Positive63 (72.4%)63 (72.4%)
PR status
 Negative24 (29.6%)27 (33.3%)0.7
 Positive57 (70.4%)54 (66.7%)
 Unknown66
HER2 status
 Balanced64 (82.1%)59 (83.1%)1
 Amplified14 (17.9%)12 (16.9%)
 Unknown916